Companies ›Consumer Cyclicals ›VNOV.PK

VNOV.PK — OTC Diversified Apparel & Accessories Makers

Vitanova Life Sciences Corp

$2,38

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

42,7 %

ROE

15,9 %

Net margin

30,8 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

2026-08-28

Ex-dividend

—

TR 1Y

—

About

Vitanova Life Sciences Corp operates in the Apparel & Accessories industry, focusing on the design, production, and distribution of consumer clothing and accessories.

Business. Vitanova Life Sciences Corp (VNOV.PK) is a diversified apparel and accessories maker operating within the Consumer Discretionary sector. The company generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. It is primarily listed on the OTC market under the ticker VNOV.PK. Headquarters location details are not provided in the available data.

Classification99 %

SectorConsumer Discretionary

Industry groupDiversified Apparel & Accessories Makers

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ2 2026 earnings (expected)2026-08-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

15,9 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning VNOV.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to VNOV.PK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Vitanova Life Sciences Corp (VNOV.PK) is a diversified apparel and accessories maker operating within the Consumer Discretionary sector. The company generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. It is primarily listed on the OTC market under the ticker VNOV.PK. Headquarters location details are not provided in the available data.

Classification99 %

SectorConsumer Discretionary

Industry groupDiversified Apparel & Accessories Makers

AI synthesis

GENERATED

Vitanova maintains a strong liquidity position with $593,040 in cash and equivalents, representing 50% of total assets, and a current ratio of 8.71, significantly above the industry median. The company is debt-free, with no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure.

Profitability metrics show a return on equity (ROE) of 15.9% and a return on assets (ROA) of 14.08%, both exceeding the industry median for Apparel & Accessories. Operating income of $232,680 and net income of $167,920 reflect strong margins, with a gross profit margin of 64.6%.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to regional economic or regulatory risks.

Vitanova's revenue growth is expected to remain stable, with no significant changes projected in the current or next fiscal year. Historical revenue of $544,590 shows consistent performance, but no growth drivers are disclosed in the available data.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares in the past year, and no dilution sources were identified in the 10-K or other filings.

Recent events include the filing of the latest financial statements, which show strong profitability and liquidity. No material events or earnings call transcripts were identified in the available data.

Key takeaways

Vitanova maintains a debt-free capital structure with a strong liquidity position.
ROE and ROA exceed industry medians, indicating strong profitability.
Revenue is concentrated in a single segment with no geographic diversification.
No immediate liquidity or dilution risks are present.
Growth trajectory is stable but lacks disclosed drivers.

Bull / Bear case

Generated · model-assisted

BULL CASE · 3

Revenue surged 366.5% year-over-year to $2.66 million, demonstrating significant top-line growth momentum for the company.

Net income expanded 503.9% to $850,750, highlighting substantial profitability improvement compared to the prior fiscal period.

The company maintains a zero long-term debt balance, resulting in a debt-to-equity ratio of 0.0.

BEAR CASE · 2

Cash conversion of -2.24 places the company in the bottom quartile, significantly underperforming the 0.49 cohort median.

Revenue volatility is evident, with FY-4 showing zero revenue and FY-2 recording only $38,000 in sales.

In focus — financials by report

Valuation FY

Market price

$2,38

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$1.1M

Net cashⓘ

$593.0k

Current ratioⓘ

8.7

Debt / equityⓘ

0.0

ROAⓘ

14.1%

ROEⓘ

15.9%

Cash conversionⓘ

-224.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs VNOV · multiples and returns

LULU—

Lululemon Athletica Inc

$123,89

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

31,8 %

— vs self

VFC—

VFC

$14,92

5,9B USD

P/E

26,8x

— vs self

Div yield

2,2 %

— vs self

ROE

13,8 %

— vs self

PVH—

Pvh Corp

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

RL—

Ralph Lauren Corp

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

LEVI—

Levi Strauss & Co.

$22,02

8,5B USD

P/E

464,2x

— vs self

Div yield

2,5 %

— vs self

ROE

0,9 %

— vs self

UA—

Under Armour Inc

$6,75

2,9B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-35,0 %

— vs self

GIL—

GIL.HM

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

KTB—

Kontoor Brands Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin42,7 %Best in class

Net Margin30,8 %Best in class

ROE15,9 %Above median

D/E0,00Above median

Cash Conv-2,24Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income
Return On Assets
net_income / total_assets

Source documents

Vitanova Life Sciences Corp Market data — financials · 2026-05-29

Ownership & reference

Insider activity

— missing data

Short positioning

33shares short0.0% vs prior

999.99days to cover

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

VNOV.PKCanonical

OTC · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Operating cash flow (annual): USD 814.41KUnknown
Revenue (annual): USD 3.03MUnknown
EPS (basic) (annual): USD-PER-SHARES -0Unknown
Pre-tax income (annual): USD 6.58KUnknown
Operating income (annual): USD 3.6KUnknown
Gross profit (annual): USD 910.59KUnknown
Net income (annual): USD -37.3KUnknown
Interest expense (annual): USD 0Unknown
Total operating expenses (annual): USD 906.99KUnknown
Cost of revenue (annual): USD 2.11MUnknown
Current ratio (FY 2026-01-31): 5.05xDerived (calculated)
Debt-to-equity (FY 2026-01-31): 0.25xDerived (calculated)
Total liabilities (YoY) (2026-01-31 vs 2025-01-31): 115.2%Derived (calculated)
Total assets (YoY) (2026-01-31 vs 2025-01-31): 75.0%Derived (calculated)
Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 67.3%Derived (calculated)
Current assets (annual): USD 2.31MSEC XBRL filing
Current liabilities (annual): USD 457.98KSEC XBRL filing
Total assets (annual): USD 2.31MSEC XBRL filing
Total liabilities (annual): USD 457.98KSEC XBRL filing
Shareholders' equity (annual): USD 1.85MSEC XBRL filing
Net income (YoY) (2025-04-30 vs 2024-04-30): 503.9%Derived (calculated)
Operating income (YoY) (2025-04-30 vs 2024-04-30): 487.6%Derived (calculated)
EPS (basic) (YoY) (2025-04-30 vs 2024-04-30): 200.0%Derived (calculated)
Cost of revenue (YoY) (2025-04-30 vs 2024-04-30): 462.9%Derived (calculated)

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-08-28EVENTUpcomingQ2 2026 earnings (expected) estimated date

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread